The Journal of Practical Medicine >
Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis
Received date: 2023-11-02
Online published: 2024-05-15
Objective To investigate the expression of zinc finger E-box-binding protein 2（ZEB2） and CC chemokine ligand 20 （CCL20） in glioma tissue and their relationship with prognosis. Methods The tumor tissues of 156 patients with glioma were collected as tumor group and 52 normal brain tissues of the same period were collected as normal group. The expression of ZEB2 and CCL20 in tissues were detected by immunohistochemistry， and the relationship between the expression and survival was analyzed by Kaplan-Meier survival curve. Patients in the tumor group were followed up for three years and grouped into a poor prognosis group and a good prognosis group based on their survival status， and the prognostic factors were analyzed by COX regression. Results The positive expression rate of ZEB2 and CCL20 in the tumor group were higher than those in the normal group （P < 0.05）. The 3-year survival rate of 156 glioma patients was 69.87%. The survival rate of patients with positive ZEB2 and CCL20 expression was lower than that of patients with negative expression （P < 0.001）. Age， maximum tumor diameter， tumor pathological grade， and positive expression of ZEB2 and CCL20 were all risk factors for poor prognosis of patients with glioma （P < 0.05）， and preoperative KPS， postoperative radiotherapy， and course of temozolomide treatment were all protective factors （P < 0.05）. Conclusion The expression level of ZEB2 and CCL20 in tumor tissues of glioma patients is up-regulated， and related to the prognosis of patients.
Shihe XIAO , Gang LI , Zhonghai LIU , Zhen. LIU . Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis[J]. The Journal of Practical Medicine, 2024 , 40(9) : 1262 -1267 . DOI: 10.3969/j.issn.1006-5725.2024.09.014
| 1 | WANG J， TANG W， YANG M， et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy ［J］. Biomaterials， 2021， 273（1）：120784-120797. doi:10.1016/j.biomaterials.2021.120784 |
| 2 | 穆素会. 贝伐单抗联合替莫唑胺治疗脑胶质瘤的临床研究［J］.实用癌症杂志， 2022， 37（4）：683-686. doi:10.3969/j.issn.1001-5930.2022.04.043 |
| 3 | QIU Z， YU Z， XU T， et al. Novel nano-drug delivery system for brain tumor treatment ［J］. Cells， 2022， 11（23）：3761-3778. doi:10.3390/cells11233761 |
| 4 | 陈思思， 邓钢. 脑胶质瘤CHSY1的表达变化及临床意义的生信分析［J］. 中国临床神经外科杂志， 2021， 26（8）：607-611. |
| 5 | 苏纯，李巧云，张燕. miR-200在子宫内膜癌组织中的表达及与ZEBZ蛋白的相关性［J］. 实用医学杂志，2016，32（18）：3057-3059. |
| 6 | MYUNG J K， CHOI S AH， KIM S K， et al. The role of ZEB2 expression in pediatric and adult glioblastomas ［J］. Anticancer Res， 2021， 41（1）：175-185. doi:10.21873/anticanres.14763 |
| 7 | 刘欣欣， 姚欣卉， 孙跃峰， 等. 乳腺癌微环境中趋化因子CCL20作用的研究进展［J］. 实用肿瘤学杂志， 2022， 36（3）：250-254. |
| 8 | SCHULZ H， DIETRICHS D， WEHLAND M， et al. In prostate cancer cells cytokines are early responders to gravitational changes occurring in parabolic flights ［J］. Int J Mol Sci， 2022， 23（14）：7876-7889. doi:10.3390/ijms23147876 |
| 9 | 闫真. ZEB2和TGF-β1在上皮性卵巢癌组织中表达的相关性及预后意义［D］. 洛阳： 河南科技大学， 2016. |
| 10 | 杨通衢， 韩志桐， 赵卫平， 等. 微流控芯技术检测循环肿瘤细胞在脑胶质瘤预后预测中的价值［J］. 中国癌症杂志， 2021， 31（10）：905-911. |
| 11 | 韦继明， 仇洪， 张传东， 等. 术中超声辅助显微切除术治疗脑胶质瘤的临床效果分析［J］. 海军医学杂志， 2022， 43（5）：527-530. doi:10.3969/j.issn.1009-0754.2022.05.019 |
| 12 | POONAN P， AGONI C， IBRAHIM M A A， et al. Glioma-targeted therapeutics： computer-aided drug design prospective ［J］. Protein J， 2021， 40（5）：601-655. doi:10.1007/s10930-021-10021-w |
| 13 | 李德培，陈忠平. 脑胶质瘤治疗现状与进展［J］. 实用医学杂志，2021，37（18）：2312-2316. doi:10.3969/j.issn.1006-5725.2021.18.002 |
| 14 | 董星艺，韩贵娟，王明华. 99Tcm标记的经聚乙二醇修饰的黑色素纳米颗粒的制备及脑胶质瘤的初步显像研究［J］. 实用医学杂志，2020，36（13）：1733-1738. doi:10.3969/j.issn.1006-5725.2020.13.009 |
| 15 | FARDI M， ALIVAND M， BARADARAN B， et al. The crucial role of ZEB2： From development to epithelial-to-mesenchymal transition and cancer complexity ［J］. J Cell Physiol， 2019， 234（9）：14783-14799. doi:10.1002/jcp.28277 |
| 16 | LEE M， LIM S， KIM Y S， et al. DEP-induced ZEB2 promotes nasal polyp formation via epithelial-to-mesenchymal transition ［J］. J Allergy Clin Immunol， 2022， 149（1）：340-357. doi:10.1016/j.jaci.2021.04.024 |
| 17 | XIE H， WU Z， LI Z， et al. Significance of ZEB2 in the immune microenvironment of colon cancer ［J］. Front Genet， 2022， 13（1）：995333-995346. doi:10.3389/fgene.2022.995333 |
| 18 | WANG K， YANG S， GAO Y， et al. MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β-catenin signaling pathway ［J］. Oncol Lett， 2020， 19（1）：992-1000. |
| 19 | CHENG H， ZHAO H， XIAO X， et al. Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124 ［J］. Mol Neurobiol， 2021， 58（3）：1006-1016. doi:10.1007/s12035-020-02165-0 |
| 20 | NAGAISHI M， FUJII Y， SUGIURA Y， et al. Increased Twist and ZEB2 expression in a cutaneous metastasis of high-grade glioma ［J］. Neuropathology， 2020， 40（2）：196-201. doi:10.1111/neup.12621 |
| 21 | KADOMOTO S， IZUMI K， MIZOKAMI A. The CCL20-CCR6 axis in Cancer progression ［J］. Int J Mol Sci， 2020， 21（15）：5186-5199. doi:10.3390/ijms21155186 |
| 22 | CHEN Z， CHEN G， ZHAO H. FDPS promotes glioma growth and macrophage recruitment by regulating CCL20 via Wnt/β-catenin signalling pathway ［J］. J Cell Mol Med， 2020， 24（16）：9055-9066. doi:10.1111/jcmm.15542 |
| 23 | FAN T， LI S， XIAO C， et al. CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition ［J］. Int J Biol Sci， 2022， 18（11）：4275-4288. doi:10.7150/ijbs.73275 |
| 24 | NAN H， ZHOU L， LIANG W， et al. Epigenetically associated CCL20 upregulation correlates with esophageal cancer progression and immune disorder ［J］. Pathol Res Pract， 2021， 228（1）：153683-153697. doi:10.1016/j.prp.2021.153683 |
| 25 | MO M， TONG S， HUANG W， et al. High serum CCL20 is associated with tumor progression in penile cancer ［J］. J Cancer， 2020， 11（23）：6812-6822. doi:10.7150/jca.48939 |
/
| 〈 |
|
〉 |